Radiation necrosis after a combination of external beam radiotherapy and iodine-125 brachytherapy in gliomas

• Main Authors: Indrawati Hadi, Daniel Reitz, Raphael Bodensohn, Olarn Roengvoraphoj, Stefanie Lietke, Maximilian Niyazi, Jörg-Christian Tonn, Claus Belka, Niklas Thon, Silke Birgit Nachbichler
• Format: Article
• Language: English
• Published: BMC 2021-02-01
• Series: Radiation Oncology
• Subjects: Radiation necrosis; Stereotactic brachytherapy; External beam radiotherapy; Re-irradiation; Prognostic factors
• Online Access: https://doi.org/10.1186/s13014-021-01762-0

Abstract Purpose Frequency and risk profile of radiation necrosis (RN) in patients with glioma undergoing either upfront stereotactic brachytherapy (SBT) and additional salvage external beam radiotherapy (EBRT) after tumor recurrence or vice versa remains unknown. Methods Patients with glioma treated with low-activity temporary iodine-125 SBT at the University of Munich between 1999 and 2016 who had either additional upfront or salvage EBRT were included. Biologically effective doses (BED) were calculated. RN was diagnosed using stereotactic biopsy and/or metabolic imaging. The rate of RN was estimated with the Kaplan Meier method. Risk factors were obtained from logistic regression models. Results Eighty-six patients (49 male, 37 female, median age 47 years) were included. 38 patients suffered from low-grade and 48 from high-grade glioma. Median follow-up was 15 months after second treatment. Fifty-eight patients received upfront EBRT (median total dose: 60 Gy), and 28 upfront SBT (median reference dose: 54 Gy, median dose rate: 10.0 cGy/h). Median time interval between treatments was 19 months. RN was diagnosed in 8/75 patients. The 1- and 2-year risk of RN was 5.1% and 11.7%, respectively. Tumor volume and irradiation time of SBT, number of implanted seeds, and salvage EBRT were risk factors for RN. Neither of the BED values nor the time interval between both treatments gained prognostic influence. Conclusion The combination of upfront EBRT and salvage SBT or vice versa is feasible for glioma patients. The risk of RN is mainly determined by the treatment volume but not by the interval between therapies.